Red light therapy — what the evidence actually shows
Photobiomodulation (PBM) — the therapeutic application of red (630-700nm) and near-infrared (700-1100nm) light at low irradiance levels — has accumulated a substantial peer-reviewed evidence base over the past decade. It is now used clinically for wound healing, musculoskeletal pain, neurological conditions and skin rejuvenation, and has entered the longevity medicine space as an adjunctive mitochondrial support therapy. This article examines the mechanism, the evidence and the clinical considerations — without the marketing hyperbole that frequently accompanies this technology.
The photobiomodulation mechanism
The primary chromophore (light-absorbing molecule) for red and near-infrared light in mammalian tissue is cytochrome c oxidase (CCO) — Complex IV of the mitochondrial electron transport chain. CCO absorbs photons at specific wavelengths (660nm and 830nm primarily) and undergoes conformational changes that dissociate inhibitory nitric oxide from the enzyme, restoring mitochondrial electron flow and increasing ATP synthesis.
Secondary mechanisms include the photodissociation of nitric oxide from haemoglobin and myoglobin (increasing local NO availability), the generation of low-level reactive oxygen species that act as second messengers activating redox-sensitive transcription factors (NF-kB, AP-1, Nrf2), and the direct activation of ion channels including TRPV1 and transient receptor potential channels.
Mitochondrial effects — the primary longevity mechanism
The mitochondrial effects of PBM are the most mechanistically credible and best characterised. Multiple controlled studies have confirmed that PBM at appropriate parameters increases ATP production in isolated mitochondria and cell cultures, reduces mitochondrial reactive oxygen species, promotes mitochondrial biogenesis through PGC-1alpha activation, and enhances mitophagy — the selective autophagy of damaged mitochondria.
A 2022 study in Redox Biology confirmed that 810nm PBM increased mitochondrial membrane potential, complex I and IV activity, and NAD+/NADH ratio in human fibroblasts under oxidative stress conditions — providing mechanistic evidence directly relevant to longevity medicine. The combination of increased ATP synthesis and restored NAD+/NADH ratio makes PBM a mechanistically plausible adjunctive NAD+ support therapy.
Anti-inflammatory effects
PBM produces dose-dependent anti-inflammatory effects through multiple mechanisms: reduction of pro-inflammatory cytokine expression (IL-1beta, TNF-alpha, IL-6), increased anti-inflammatory IL-10 production, mast cell stabilisation, and reduction of NF-kB activation in chronically inflamed tissues. A 2023 systematic review in Journal of Inflammation Research confirmed that PBM significantly reduced CRP and IL-6 in clinical trials across musculoskeletal, cardiovascular and metabolic conditions.
Cognitive and neurological evidence
Transcranial PBM — the application of near-infrared light directly to the skull — has produced cognitive improvements in randomised trials of Alzheimer's disease, traumatic brain injury and normal ageing. A 2017 randomised trial in Photobiomodulation, Photomedicine, and Laser Surgery confirmed that twice-weekly transcranial PBM significantly improved reaction time, memory, attention and processing speed in healthy adults over 12 weeks. A 2023 RCT in healthy older adults confirmed PBM-associated improvements in executive function and working memory correlated with increased prefrontal cortex blood oxygenation.
The mechanism is consistent with the mitochondrial model: increased CCO activity in cortical neurons drives greater ATP availability for synaptic function. The vasodilatory effects of photodissociated nitric oxide increase regional cerebral blood flow. Both mechanisms support improved neuronal function without pharmacological intervention.
Skin and collagen evidence
PBM has the most robust clinical evidence base in dermatology. Multiple RCTs have confirmed that red and near-infrared light increases collagen synthesis in dermal fibroblasts, reduces inflammatory skin conditions, promotes wound healing and reduces photoageing markers. A 2014 RCT in Photomedicine and Laser Surgery confirmed that combined 633nm and 830nm PBM produced significant improvements in skin tone, wrinkle reduction and collagen density over 30 sessions compared to placebo.
Clinical considerations and parameters
Therapeutic PBM requires attention to wavelength (630-670nm red, 810-850nm NIR), irradiance (10-100 mW/cm²), energy density (1-10 J/cm² for most applications) and treatment frequency. Higher is not better — biphasic dose-response curves mean that excessive irradiance or energy density can produce inhibitory effects. Full-body PBM panels used in longevity clinics (red-infrared floor-to-ceiling panels) typically deliver 10-15 minutes of whole-body exposure at therapeutic parameters.
Contraindications include active malignancy in the treatment area, photosensitising medications and direct eye exposure. PBM is contraindicated over the thyroid in individuals with active thyroid disease. In the context of a comprehensive longevity protocol, PBM is best understood as an adjunctive mitochondrial and anti-inflammatory support rather than a primary intervention.
Incorporate evidence-based longevity therapies
The Longevity Blueprint includes biohacking referrals for PBM, HBOT and infrared sauna where clinically indicated. Every enquiry begins with a complimentary Discovery Call.
Book a complimentary Discovery Call View The Longevity BlueprintReferences
- Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics. 2017;4(3):337-361.
- Karu TI. Mitochondrial signaling in mammalian cells activated by red and near-IR radiation. Photochemistry and Photobiology. 2008;84(5):1091-1099.
- Begum R, Powner MB, Hudson N, Hogg C, Jeffery G. Treatment with 670 nm light up regulates cytochrome C oxidase expression and reduces inflammation in an age-related macular degeneration model. PLOS ONE. 2013;8(2):e57828.
- Naeser MA, Saltmarche A, Krengel MH, Hamblin MR, Knight JA. Improved cognitive function after transcranial, light-emitting diode treatments in chronic, traumatic brain injury: two case reports. Photomedicine and Laser Surgery. 2011;29(5):351-358.
- Avci P, Gupta A, Sadasivam M, et al. Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Seminars in Cutaneous Medicine and Surgery. 2013;32(1):41-52.
- Ferraresi C, Huang YY, Hamblin MR. Photobiomodulation in human muscle tissue: an advantage in sports performance? Journal of Biophotonics. 2016;9(11-12):1273-1299.
- de la Torre JC. Treating cognitive impairment with transcranial low level laser therapy. Journal of Photochemistry and Photobiology B. 2017;168:149-155.
- Wunsch A, Matuschka K. A controlled trial to determine the efficacy of red and near-infrared light treatment in patient satisfaction, reduction of fine lines, wrinkles, skin roughness, and intradermal collagen density increase. Photomedicine and Laser Surgery. 2014;32(2):93-100.
- Huang YY, Chen AC, Carroll JD, Hamblin MR. Biphasic dose response in low level light therapy. Dose Response. 2009;7(4):358-383.
- Dompe C, Moncrieff L, Matys J, et al. Photobiomodulation — underlying mechanism and clinical applications. Journal of Clinical Medicine. 2020;9(6):1724.
Longevity Medicine Series — all articles
NAD+ Biological age Autophagy Muscle & longevity Senescent cells Inflammageing Brain health Red light therapy Peptides GLP-1 & berberine Post-pill recovery Gut & longevity Mitochondria Sleep & longevity Testosterone & women Methylation & MTHFR Omega-3 Fasting & TRE Microbiome & longevity Cardiovascular longevity Perimenopause & menopause Vitamin D & longevity Epigenetic clocks Longevity consultation